Daxor Corporation (DXR) - Total Liabilities
Based on the latest financial reports, Daxor Corporation (DXR) has total liabilities worth $272.43K USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Daxor Corporation's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Daxor Corporation - Total Liabilities Trend (1985–2024)
This chart illustrates how Daxor Corporation's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Daxor Corporation.
Daxor Corporation Competitors by Total Liabilities
The table below lists competitors of Daxor Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dynamic Medical Technologies
TWO:4138
|
Taiwan | NT$1.35 Billion |
|
Shanghai Jin Jiang International Industrial Investment Co Ltd B
SHG:900914
|
China | $1.14 Billion |
|
Regis Corporation Common Stock
NASDAQ:RGS
|
USA | $353.41 Million |
|
Pasupati Acrylon Limited
NSE:PASUPTAC
|
India | Rs2.63 Billion |
|
Mordechai Aviv Taasiot Beniyah 1973 Ltd
TA:AVIV
|
Israel | ILA462.10 Million |
|
Titijaya Land Bhd
KLSE:5239
|
Malaysia | RM1.04 Billion |
|
PicoCELA Inc. American Depositary Shares
NASDAQ:PCLA
|
USA | $624.90 Million |
|
Enex Co.Ltd
KO:011090
|
Korea | ₩86.81 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Daxor Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Daxor Corporation to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daxor Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daxor Corporation (1985–2024)
The table below shows the annual total liabilities of Daxor Corporation from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $840.30K | -2.15% |
| 2023-12-31 | $858.76K | -33.51% |
| 2022-12-31 | $1.29 Million | -66.27% |
| 2021-12-31 | $3.83 Million | +336.26% |
| 2020-12-31 | $877.69K | -38.85% |
| 2019-12-31 | $1.44 Million | -68.55% |
| 2018-12-31 | $4.56 Million | -17.81% |
| 2017-12-31 | $5.55 Million | +5.18% |
| 2016-12-31 | $5.28 Million | -18.34% |
| 2015-12-31 | $6.47 Million | -69.88% |
| 2014-12-31 | $21.47 Million | +2.10% |
| 2013-12-31 | $21.02 Million | -0.91% |
| 2012-12-31 | $21.22 Million | -57.15% |
| 2011-12-31 | $49.51 Million | +12.01% |
| 2010-12-31 | $44.20 Million | +60.37% |
| 2009-12-31 | $27.56 Million | -17.39% |
| 2008-12-31 | $33.36 Million | -29.97% |
| 2007-12-31 | $47.64 Million | +46.47% |
| 2006-12-31 | $32.53 Million | +56.23% |
| 2005-12-31 | $20.82 Million | +29.74% |
| 2004-12-31 | $16.05 Million | +35.05% |
| 2003-12-31 | $11.88 Million | +48.05% |
| 2002-12-31 | $8.03 Million | -2.25% |
| 2001-12-31 | $8.21 Million | -24.69% |
| 2000-12-31 | $10.90 Million | +66.04% |
| 1999-12-31 | $6.57 Million | -25.38% |
| 1998-12-31 | $8.80 Million | +4.76% |
| 1997-12-31 | $8.40 Million | +52.73% |
| 1996-12-31 | $5.50 Million | -1.79% |
| 1995-12-31 | $5.60 Million | +43.59% |
| 1994-12-31 | $3.90 Million | -17.02% |
| 1993-12-31 | $4.70 Million | -54.37% |
| 1992-12-31 | $10.30 Million | +1.98% |
| 1991-12-31 | $10.10 Million | -9.01% |
| 1990-12-31 | $11.10 Million | +42.31% |
| 1989-12-31 | $7.80 Million | -30.97% |
| 1988-12-31 | $11.30 Million | +44.87% |
| 1987-12-31 | $7.80 Million | +11.43% |
| 1986-12-31 | $7.00 Million | +52.17% |
| 1985-12-31 | $4.60 Million | -- |
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corpo… Read more